)
Covalon Technologies (COV) investor relations material
Covalon Technologies Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue reached $10,041,033 (CAD 10 million), up 20% year-over-year, with growth across all sales channels, led by U.S. vascular access and contamination protection solutions.
Gross profit rose 73% to $6,745,607 (CAD 6.7 million), with gross margin improving to 67.2% from 46.5% last year, driven by high-margin U.S. vascular business and favorable inventory adjustments.
Net income for Q3 was $2,810,837 (CAD 2.8 million), a significant increase from the prior year; adjusted EBITDA was $3.0 million, more than triple last year.
Cash position increased to $19.4 million at quarter-end, up $2.8 million from the previous quarter, with no bank debt.
All key financial metrics—revenue, gross profit, gross margin, adjusted gross margin, and adjusted EBITDA—were the highest in any quarter in the past five years.
Financial highlights
Q3 gross margin was 67.2%, up from 46.5% last year; adjusted gross margin was 66.4% versus 55.6%.
Operating expenses remained stable at $4,018,397 (CAD 4 million), up just 1% year-over-year.
Generated $7.4 million in operating cash flow in nine months, up from $3.0 million last year.
Paid out $4.1 million in the first-ever dividend and invested over $1 million in capital expenditures.
Year-to-date revenue was $25,656,349 (CAD 26 million), up 6% year-over-year, with net income more than doubling to $4 million and EPS rising to $0.15.
Outlook and guidance
Management expressed strong optimism for continued growth, citing robust sales momentum, expanding adoption of key products, and a robust pipeline for hospital opportunities.
Investments in manufacturing and regulatory submissions are expected to support future efficiency and international expansion.
Fiscal 2026 is on track for strong performance, with growth expected to continue into next year and beyond.
Focus remains on expanding contamination protection solutions and driving value creation.
Management highlights massive further opportunity with existing account penetration and new account acquisition.
- Q2 revenue up 14.9% with margin expansion and rapid clinical product adoption.COV
Q2 2026 - Q2 sales and orders already exceed Q1, supporting a strong outlook and industry momentum.COV
Q1 2026 - Record Q4 revenue, $0.15 dividend, $17M cash, and strong growth in key channels.COV
Q4 2025 - Strong U.S. growth, clinical impact, and a special dividend highlight strategic momentum.COV
Planet MicroCap Showcase: TORONTO 2025 - Sequential revenue and EBITDA growth, strong cash, and new clinical evidence drive outlook.COV
Q3 2025 - Strong U.S. growth, profitability turnaround, and innovation position the company for expansion.COV
Planet MicroCap Showcase: VANCOUVER 2024 - Q3 revenue up 47% to $9.2M, with adjusted EBITDA of $2.4M and EPS of $0.06.COV
Q3 2024 - 75% revenue growth and strong US consumables sales drove profitability and industry recognition.COV
Q1 2025 - Double-digit revenue growth, positive net income, and strong cash position in FY2024.COV
Q4 2024
Next Covalon Technologies earnings date
Next Covalon Technologies earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)